Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Site of mitomycin-C application during trabeculectomy. J Glaucoma 1994;3(4):296-301

Date

01/01/1994

Pubmed ID

19920613

Abstract

The outcome and postoperative complications after trabeculectomies with mitomycin-C application before flap dissection (episcleral) or after flap dissection (scleral bed) were analyzed retrospectively in 82 patients (82 eyes). Thirty-six eyes (43.9%) had an episcleral mitomycin-C application, and 46 (56.1%) had scleral-bed mitomycin-C administration. After a mean follow-up of 10.1 +/- 3.8 months and 9.9 +/- 4.3 months for the episcleral and scleral-bed groups, respectively, complete success (intraocular pressure </=21 mm Hg without medications) was achieved in 18 eyes (50%) in the episcleral group and in 43 eyes (93.5%) in the scleral-bed group. Qualified success (intraocular pressure </=21 mm Hg with glaucoma medications) was achieved in 10 eyes (27.8%) in the episcleral group and in 8 eyes (17.4%) in the scleral-bed group. Rates of cumulative survival and time of trabeculectomy survival were statistically higher in the scleral bed group (p = 0.002 and 0.0004, respectively). There was a statistically significant difference in the success rates between groups (p = 0.03). The final intraocular pressure was significantly lower in the scleral-bed group (p = 0.015). There were no differences in duration of postoperative follow-up or frequency of complications. Mitomycin-C application after the scleral flap dissection appears to be associated with higher success rates than mitomycin-C application before scleral flap dissection.

Author List

Prata JA Jr, Minckler DS, Baerveldt G, Lee PP, Heuer DK

Author

Dale Heuer MD Emeritus Professor in the Ophthalmology department at Medical College of Wisconsin